These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19188312)

  • 1. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
    Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
    Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.
    Smorodinsky E; Ansdell DS; Foster ZW; Mazhar SM; Cruite I; Wolfson T; Sugay SB; Iussich G; Shiehmorteza M; Kono Y; Kuo A; Sirlin CB
    J Magn Reson Imaging; 2015 May; 41(5):1259-67. PubMed ID: 24811860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.
    Tsushima Y; Kanal E; Thomsen HS
    Br J Radiol; 2010 Jul; 83(991):590-5. PubMed ID: 20413447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
    Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
    JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
    Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
    Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of nephrogenic systemic fibrosis at two large medical centers.
    Prince MR; Zhang H; Morris M; MacGregor JL; Grossman ME; Silberzweig J; DeLapaz RL; Lee HJ; Magro CM; Valeri AM
    Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
    Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
    Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.
    Bäuerle T; Saake M; Uder M
    Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
    Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
    Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
    Zou Z; Zhang HL; Roditi GH; Leiner T; Kucharczyk W; Prince MR
    JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
    Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
    Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The need for prophylactic hemodialysis to protect against nephrogenic systemic fibrosis in patients with end-stage renal disease receiving gadolinium-based contrast agents.
    Lee Y; Kim J; Kwon S; Jeong JC; Joo KW; Oh KH
    Acta Radiol; 2023 Aug; 64(8):2492-2496. PubMed ID: 37128169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of nephrogenic systemic fibrosis in liver transplantation patients.
    Chow DS; Bahrami S; Raman SS; Rotchel S; Sayre JW; Busuttil RW; Lu DS
    AJR Am J Roentgenol; 2011 Sep; 197(3):658-62. PubMed ID: 21862808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.
    Alfano G; Fontana F; Ferrari A; Solazzo A; Perrone R; Giaroni F; Torricelli P; Cappelli G
    Magn Reson Imaging; 2020 Jul; 70():1-4. PubMed ID: 32112811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
    Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
    Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.